Leslie Stolz, Ph.D.
Vice President, Regulatory Affairs
Leslie Stolz is vice president of regulatory affairs at Verve Therapeutics. She has 18 years of experience in the life sciences industry, with extensive drug development experience, and has worked in multiple therapeutic areas including immunology, cardiology, and rare diseases. Prior to joining Verve, Dr. Stolz was vice president, regulatory strategy at Syntimmune, until it was sold to Alexion in 2018. She has held a number of positions at Shire, Dyax and Boston Scientific in areas such as regulatory affairs, medical affairs and medical communications. Dr. Stolz has a Ph.D. in molecular cancer biology from Duke University and a B.S. in honors biology from Villanova University. She was a postdoctoral fellow in the Department of Cardiovascular and Metabolic Diseases Research at Wyeth Research (now Pfizer).